Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||XL228||Phase I||Actionable||In a Phase I trial, XL228 treatment resulted in stable disease for 12 weeks or longer in 31% (25/80) of patients with an advanced solid tumor and a partial response in one patient (J Clin Oncol 28:15s, 2010 (suppl; abstr 3105)).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma||Full reference...|